• 6 min read
• Published on 4 April 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Tariff Shock. Washington is threatening a massive tax on imported medicines. It is a harsh wake-up call for global drugmakers who must now build in America or face ruinous costs.
The Outsourcing Rush. Smart money is pivoting to domestic contract manufacturers. These US Pharma Reshoring | CDMOs & Supply Chain Stocks stocks offer a ready-built solution for executives reshaping their drug manufacturing pipelines.
The Infrastructure Play. The opportunity goes far beyond factory walls. Watching the news, investment opportunities like this rarely emerge with such scale. Anyone exploring US Pharma Reshoring | CDMOs & Supply Chain Stocks investing, from Africa to Europe, might find value in the distributors powering this domestic shift.
The Waiting Game. Building factories takes years, and political winds often change. While fractional shares in these companies provide accessible entry points, investors must understand that policy reversals could easily derail this momentum.
For decades, the pharmaceutical playbook was brutally simple.
Invent a medicine in Boston, manufacture it in Mumbai, and sell it back to New York for a massive premium. It was a beautifully efficient machine.
Then Washington changed the rules.
The administration introduced the prospect of tariffs up to 100 percent on imported brand-name drugs. If a company manufactures a pill abroad and sells it in America, it could face a tax equal to the entire value of the product. That is not a subtle policy nudge. That is a brick wall.
In previous years, the idea of domestic manufacturing was an afterthought. Then, the threat of these tariffs changed everything. Industry leaders suddenly realised their ossified supply chains were a massive liability. They panicked, pledging an estimated 400 billion dollars in capital expenditure to comply with new federal requirements.
That is a colossal restructuring of wealth.
The message from the top is clear. Produce in America, or pay the price. However, not every pharmaceutical giant wants to build a new factory. Building from scratch takes years of planning, endless permits, and billions of dollars.
This is where the quiet middlemen step in. Contract Development and Manufacturing Organisations, or CDMOs, are essentially the landlords of the drug world. They already have the pristine cleanrooms and the regulatory approvals. If a major drugmaker needs domestic capacity immediately, they don't pour concrete. They sign a contract.
To me, this dynamic is exactly what makes the US Pharma Reshoring | CDMOs & Supply Chain Stocks basket so compelling to watch. It captures the businesses that are quietly supplying the shovels for this modern gold rush.
You can't ignore the massive players who already hold the keys to domestic production.
Companies like Eli Lilly and Pfizer already possess significant manufacturing infrastructure on American soil. Pfizer has a distinct home-field advantage. Expanding an existing plant is considerably faster than breaking ground on a new one. Merck also holds a substantial domestic footprint, which might allow it to sidestep punishing import costs entirely.
These firms aren't speculative startups. They are established behemoths with the balance sheets to absorb massive capital expenditure.
I think it's crucial to remain pragmatic here. This theme carries real conviction, but it also carries real risk.
The policy environment is brittle. Trade negotiations and political priorities could easily alter the trajectory of these tariffs. If the political winds change, companies that committed billions to domestic factories might face severe execution risks.
Furthermore, infrastructure investments don't deliver returns overnight. This is a slow, methodical repositioning of global supply chains. Value appreciation here might be entirely gradual. Capital is always at risk, and you must accept that past performance provides absolutely no guarantee of future returns.
The reshuffling of global healthcare logistics is underway. The companies positioned to catch this wave have credible reasons to be watched closely, provided you have the patience to see how the dust settles.
View the full Basket:US Pharma Reshoring | CDMOs & Supply Chain Stocks
View the full Basket:US Pharma Reshoring | CDMOs & Supply Chain Stocks
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article